Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.

被引：0
|
作者：
Engel-Nitz, Nicole M.
Becker, Laura
Gerdes, Randall
Hao, Yanni
机构：
[1] Optum, Eden Prairie, MN USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11504
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [22] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [23] COMPARATIVE EFFECTIVENESS OF EVEROLIMUS VS. FULVESTRANT MONOTHERAPY AMONG POSTMENOPAUSAL WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER
    Lin, P. L.
    Hao, Y.
    Xie, J.
    Li, N.
    Ohashi, E.
    Koo, V
    Wu, E. Q.
    VALUE IN HEALTH, 2015, 18 (03) : A192 - A192
  • [24] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [25] Abemaciclib for treating patients with HR+/HER2-metastatic breast cancer: a real-world study in France, Italy and Spain
    Blancas, Isabel
    Grosjean, Jessica
    Pedersini, Rebecca
    Buzzoni, Carlotta
    Sleilaty, Ghassan
    Molero, Alberto
    Tamma, Antonella
    Chouaki, Nadia
    Atienza, Manuel
    Emde, Anna
    Siddi, Sara
    Bayona, Rodrigo Sanchez
    Del Mastro, Lucia
    Fakhouri, Walid
    FUTURE ONCOLOGY, 2024, 20 (31) : 2371 - 2384
  • [26] Initial real world treatment patterns and outcomes of Abemaciclib for the treatment of HR+,HER2-metastatic breast cancer
    Carter, Gebra Cuyun
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Smith, Emily Nash
    Mathur, Raina
    Cohen, Aaron B.
    Baxi, Shrujal
    Rybowski, Sarah
    Chong, Amy Lee
    Seidman, Andrew D.
    CANCER RESEARCH, 2020, 80 (04)
  • [27] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer
    Hamilton, E. P.
    Cortes, J.
    Ozyilkan, O.
    Chen, S-C.
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Huober, J.
    Chapman, S. C.
    Yang, Z.
    Chen, Y.
    Johnston, E. L.
    Martin, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S348 - S348
  • [28] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, Her2-metastatic breast cancer
    Huober, J.
    Hamilton, E.
    Cortes, J.
    Ozyilkan, O.
    Chen, S. C.
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Chapman, S.
    Yang, Z.
    Chen, Y.
    Johnston, E.
    Martin, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 244 - 245
  • [29] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [30] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
12345